蘇祐立
長庚醫療財團法人高雄長庚紀念醫院
國語,英語,閩南語 副教授
泌尿上皮癌、大腸直腸癌、腎臟癌、攝護腺癌、軟組織肉瘤、癌症精準藥物治療、免疫治療、新藥臨床試驗
蘇祐立看診時間
| 星期一 | 24 小時營業 |
| 星期二 | 24 小時營業 |
| 星期三 | 24 小時營業 |
| 星期四 | 24 小時營業 |
| 星期五 | 24 小時營業 |
| 星期六 | 24 小時營業 |
| 星期日 | 24 小時營業 |
蘇祐立醫師簡介
現職
- 高雄長庚血液腫瘤科副科主任
- 高雄長庚血液腫瘤科主治醫師
學歷
- 中國醫藥大學 中醫系雙主修醫學士
經歷
- 高雄長庚血液腫瘤科主治醫師
學會與認證
- 中華民國癌症醫學會
- 台灣內科醫學會
論文及期刊發表
- Galectin-1 overexpression activates the FAK/PI3K/AKT/mTOR pathway and is correlated with upper urinary urothelial carcinoma progression and survival. Cells 2020, 9(4):806 (SCI; IF=4.366; Cell biology, 70/195 First and corresponding author)
Su YL*, Luo HL, Huang CC, Liu TT, Huang EY, Sung MT, Lin JJ, Chiang PH, Chen YT, Kang CH, Cheng YT. - Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders. PLos One 2020; 15(2):e0229263. (SCI; IF=2.740; Multidisciplinary sciences 27/71)
Liu JM, Liu YP, Chuang HC, Wu CT, Su YL, Hsu RJ. - Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med 2020; 9(1): E188. (SCI; IF=3.303; Medicine, General & internal 36/165)
Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. - Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019. (SCI; IF=33.752; Oncology 4/244)
Petrylak DP, de Wit R, Chi KN…Su YL…et al. - A Narrative Review of Complementary Nutritional Supplements for Chemotherapy-induced Peripheral Neuropathy. Altern Ther Health Med 2019 (SCI; IF=0.937; Integrative complementary medicine 25/28)
Liu YW, Liu CT, Su YL, Tsai MY. - Comparative study of the safety and efficacy of
first-line cisplatin and carboplatin chemotherapy in elderly patients with metastatic
urothelial carcinoma. Oncology 2020;98:146-153 (SCI; IF=2.642; Oncology 162/244, Corresponding author)
Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su YL*. - Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through
the MAPK Pathway. Molecules 2019, 24(20): 3707. (SCI; IF=3.267; Chemistry,
multidisciplinary 70/177)
Luo HL, Chen IH , Su YL, Huang CC, Chiang PH, Yu CC, Lee NL, Lin JJ, Sung MT*. - Presence of
Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer
Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
(EGFR-TKI): A Nationwide, Population-Based Cohort Study. J Clin Med 2019,
8(7):1024. (SCI; IF=3.303; Medicine, General & internal 36/165, Corresponding
author)
Wu CC, Rau KM, Lee WC, Hsieh MC, Liu JC, Chen YY, Su YL*. - Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced
Upper Urinary Tract Urothelial Carcinoma. Int J Mol Sci 2019; 20(7):E1653. doi:
10.3390/ijms20071653. (SCI; IF=4.556; Biochemistry &
Molecular Biology 74/297)
Luo HL, Chiang PH, Huang CC, Su YL, Sung MT, Tsai EM, Lin CS, Chiang PH*. - Developing a multivariable normal tissue complication probability model to predict
late rectal bleeding following intensity-modulated radiation therapy. J Cancer 2019; 10(11):2588-2593. (SCI; IF=3.565; Oncology 105/244)
Huang CC, Chao PJ, Guo SS, Wang CJ, Luo HL, Su YL, Lee TF, Fang FM*. - Gender is a
significant prognostic factor for upper urinary tract urothelial carcinoma: A large
hospital-based cancer registry study in an endemic area. Front. Oncol. 9:157. (SCI;
IF=4.848; Oncology 69/244)
Huang CC, Su YL, Luo HL, Chen YT, Sio TT, Hsu HC, Lai CH*. - Proteomics
analysis of Tangeretin-induced apoptosis through mitochondrial dysfunction in
bladder cancer cells. Int J Mol Sci 2019; 20:E1017. (SCI; IF=4.556; Biochemistry &
Molecular Biology 74/297)
Lin JJ, Huang CC, Su YL, Luo HL, Lee NL, Wu YJ, Sung MT *. - A review of
Complementary therapies with medicinal plants for chemotherapy-induced
peripheral neuropathy. Complement Ther Med 2019; 42:226-323. (SCI; IF=2.063;
Integrative & Complementary medicine 14/28)
Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY*. - Impact of Prognostic Nutritional Index on Overall Survival for Patients
with Metastatic Urothelial Carcinoma. J Cancer 2018, 14;9(14):2466-2471. (SCI; IF=3.565; Oncology 105/244, Corresponding author)
Hsieh MC, Rau KM, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Huang CH, Su YL*. - Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. Asia Pac J Clin Oncol 2018, 14:353-360. (SCI; IF=2.012; Oncology 201/244)
Huang PW, Chou WC, Shen WC, Hung CY, Huang KG, Su YL, Lu CH, Chang YS, Liau CT*. - Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. Sci Rep. 2018; 8(1):7485. (SCI; IF=3.998; Multidisciplinary Sciences 17/71)
Huang HS, Su YL, Li PH, Chiang PH, Huang CH, Chen CH, Hsieh MC*. - Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient with Metastatic Clear-cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2018; 16(2):114-6. (SCI; IF=2.695; Urology & Nephrology 30/85)
Su YL*. - High expression of endoglin in primary breast cancermay predict response to neoadjuvant chemotherapy. Mol Med Rep. 2017; 16(5):7185-7190. (SCI; IF=2.100; Medicine, research & experimental 96/138)
Rau KM*, Su YL, Li SH, Hsieh, MC Wu CC, Chou FF, Chiu Tai Jan, Chen Yen, Hao, Liu Chien Tin. - Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017; 390(10109):2266-2277. (SCI; IF=60.392; Medicine, General & internal 2/165)
Petrylak DP, de Wit R, Chi KN…Su YL…et al. - Therapeutic outcome of nasopharyngeal carcinoma with cranial nerve palsy: a single institution experience of 104 patients. OncoTargets Ther. 2017 Apr10;10:2069-2075. (SCI; IF=3.337; Biotechnology & applied microbiology 56/156)
Huang CC*, Fang FM, Chen HC, Hsu HC, Huang TL, Su YL, Chang YC. - Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. PLOS One 10(6): e0129268. (SCI; IF=2.740; Multidisciplinary sciences 27/71, first author)
Su YL, Hsieh MC, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Hung CH, Tang Y, Rau KM*. - Left ventricular intracavitary and intramyocardial metastases from renal cell carcinoma. J Echocardiogr. 2017; 15(3):143-144. (non-SCI)
Lee WC, Liu WH, Su YL*. - A preliminary randomised controlled study of short-term Antrodia
cinnamomea treatment combined with chemotherapy for patients with advanced
cancer. BMC Complement Altern Med 2016; 16(1):322. (SCI; IF=2.833; Integrative
& Complementary medicine 6/28)
Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH, Rau KM*. - Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. J Cancer 2016; 27:1347-52. (SCI; IF=3.565; Oncology 105/244, Corresponding author )
Hsieh MC, Huang CH, Chiang PH, Chen YY, Tang Y, Su YL*. - The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia Pac J Clin Oncol 2016; 12(4):396-402. (SCI; IF=2.012; Oncology 201/244)
Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chen YY, Chou WC*. - Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. Int J Urol 2016; 23:385-389. (SCI; IF=2.445; UROLOGY & NEPHROLOGY 36/85)
Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH*. - The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. Urol Oncol. 2015 Nov;33(11):495.e9-14. (SCI; IF=2.882; UROLOGY & NEPHROLOGY 28/85)
Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH* - Asthma and Risk of Prostate Cancer: A Population-based Case-Cohort Study in Taiwan. Medicine, 2015; 94(36): e1371. (SCI ; IF=1.552 MEDICINE, GENERAL & INTERNAL 89/165)
Su YL, Chou CL, Rau KM, Charles Lee TC*. - The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma. PLoS One. 2015 Jun 26;10(6):e0129268. (SCI; IF=2.740; Multidisciplinary sciences 27/71; Corresponding author)
.Hsieh MC, Sung MT, Chiang PH, Huang CH, Tang Y, Su YL* - Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-positive Lung Adenocarcinoma. J Thorac Oncol. 2015; 10(4):e21-22 (SCI ; IF=13.357 ; Respiratory System 3/64)
Su YL, Rau KM*. - Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Radiology and oncology. 2014;48:314-322. (SCI ; IF=1.746 ; Radiology, Nuclear medicine & Medical imaging 92/133;first author)
Su YL, Li SH, Chen YY , Chen HC, Tang Y, Huang CH, Chou FF, Wu SC, Rau KM*. - Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. Sci World J. 2014:160138 (non-SCI).
Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, Su YL, Chen YH, Lu SN, Rau KM*.